Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled deutetrabenazine trial in pediatric dyskinetic cerebral palsy
MOH_2019-10-07_007177Phase 3Not yet recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyskinesia and dyskinetic cerebral palsy (DCP) comparing TEV-50717 / Austedo with Placebo (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
deutetrabenazine
03
Conditions
dyskinesiadyskinetic cerebral palsy (DCP)
Beyond the preview
Go deeper on MOH_2019-10-07_007177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-07_007177.